Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

NCT03948178 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

227

Enrollment

INDUSTRY

Sponsor class

Stopped This was an open label extension for patients completing the REFALS study (3119002; NCT03505021). Study 3119002 showed lack of efficacy of ODM109 so the sponsor decided to terminate this study

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: Levosimendan

Sponsor

Orion Corporation, Orion Pharma